ライフサイエンスコーパス: fatigue syndrome

1 gnostic criteria for neurasthenia or chronic fatigue syndrome.

2 the current state of knowledge about chronic fatigue syndrome.

3 oes not seem to be beneficial in the chronic fatigue syndrome.

4 relaxation therapy for patients with chronic fatigue syndrome.

5 tant in both chronic fatigue and the chronic fatigue syndrome.

6 There is mild hypocortisolism in chronic fatigue syndrome.

7 ctor contributing to the symptoms of chronic fatigue syndrome.

8 of well-characterized patients with chronic fatigue syndrome.

9 such as irritable bowel syndrome and chronic fatigue syndrome.

10 cidality adequately in patients with chronic fatigue syndrome.

11 drome, heat intolerance, and perhaps chronic fatigue syndrome.

12 documented in both fibromyalgia and chronic fatigue syndrome.

13 documented in both fibromyalgia and chronic fatigue syndrome.

14 virus and Still's disease as well as chronic fatigue syndrome.

15 ic stress disorder, and possibly the chronic fatigue syndrome.

16 tibodies in sera of 60 patients with chronic fatigue syndrome.

17 dence for an autoimmune component in chronic fatigue syndrome.

18 e entry) and received a diagnosis of chronic fatigue syndrome.

19 T and SMC plus GET for patients with chronic fatigue syndrome.

20 apy (APT) plus SMC and SMC alone for chronic fatigue syndrome.

21 hysical disability for patients with chronic fatigue syndrome.

22 rpetuating fatigue and disability in chronic fatigue syndrome.

23 iating symptoms of depression and in chronic fatigue syndrome.

24 vation approached levels observed in chronic fatigue syndrome.

25 le bowel syndrome, fibromyalgia, and chronic fatigue syndrome.

26 iated with human prostate cancer and chronic fatigue syndrome.

27 able to previously described post-infectious fatigue syndrome.

28 medical care (SMC) for patients with chronic fatigue syndrome.

29 ation with human prostate cancer and chronic fatigue syndrome.

30 rus linked to prostate carcinoma and chronic fatigue syndrome.

31 n the human gammaretrovirus XMRV and chronic fatigue syndrome.

32 ostpoliomyelitis, poststroke, and in chronic fatigue syndrome.

33 r postinfectious irritable bowel and chronic fatigue syndromes.

34 logical distress in chronic pain and chronic fatigue syndromes.

35 attributable to the chronic pain and chronic fatigue syndromes.

36 prostate cancer and in patients with chronic fatigue syndromes.

37 physical functioning in people with chronic fatigue syndrome 1 year after randomisation.

38 An empirically defined fatigue syndrome 6 months after onset, which excluded co

39 The predictors of a prolonged fatigue syndrome after an infection differ with both def

40 The chronic fatigue syndrome also presents problems in definition an

41 ation with human prostate cancer and chronic fatigue syndrome, although these associations are contro

42 s meeting international criteria for chronic fatigue syndrome and 329 participants meeting London cri

43 121 consecutive clinic patients with chronic fatigue syndrome and 64 comparison subjects without the

44 ic biomarker of MMF in patients with chronic fatigue syndrome and cognitive dysfunction.

45 confirmed an association between the chronic fatigue syndrome and orthostatic intolerance; however, t

46 coronary heart disease, cancer, and chronic fatigue syndrome and those remaining on their initial re

47 sought predictors of both acute and chronic fatigue syndromes and mood disorders from clinical, labo

48 ine and fibromyalgia', 'Dopamine and chronic fatigue syndrome' and 'Dopamine and irritable bowel synd

49 clear envelope proteins was found in chronic fatigue syndrome, and an increased prevalence of antipol

50 ssants for irritable bowel syndrome, chronic fatigue syndrome, and chronic back pain were selected fo

51 tation, evaluation, and prognosis of chronic fatigue syndrome are discussed.

52 C to moderately improve outcomes for chronic fatigue syndrome, but APT is not an effective addition.

53 an effective and safe treatment for chronic fatigue syndrome, but it is therapist intensive and avai

54 d all-cause mortality in people with chronic fatigue syndrome, but our findings show a substantial in

55 GET) can be effective treatments for chronic fatigue syndrome, but patients' organisations have repor

56 in blood samples from patients with chronic fatigue syndrome, but these findings have not been repli

57 Cognitive behavior therapy for chronic fatigue syndrome can produce some lasting benefits but i

58 ss in a case series of patients with Chronic Fatigue Syndrome (CFS) after the infection.

59 1994 criteria were used to diagnose chronic fatigue syndrome (CFS) and idiopathic chronic fatigue (I

60 Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are associated with substantial p

61 Patients with chronic fatigue syndrome (CFS) are more likely than healthy pers

62 in the blood of 67% of patients with chronic fatigue syndrome (CFS) compared with 3.7% of healthy con

63 nt reports showed many patients with chronic fatigue syndrome (CFS) harbor a retrovirus, xenotropic m

64 Gulf War Illness (GWI) and Chronic Fatigue Syndrome (CFS) have similar profiles of pain, fa

65 ogy, and treatment of postinfectious chronic fatigue syndrome (CFS) in adolescents.

66 associated with prostate cancer and chronic fatigue syndrome (CFS) in recent years.

67 sorder (PTSD) and illness resembling chronic fatigue syndrome (CFS) in the entire population of Gulf

68 Chronic fatigue syndrome (CFS) is a complex, heterogeneous disea

69 Chronic fatigue syndrome (CFS) is a debilitating disease of unkn

70 Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a debilitating multisystem con

71 Chronic fatigue syndrome (CFS) is a disabling condition with unk

72 Chronic fatigue syndrome (CFS) is a multisystem disorder charact

73 Chronic fatigue syndrome (CFS) is a serious systemic illness of

74 Chronic fatigue syndrome (CFS) is an important public health pro

75 Chronic fatigue syndrome (CFS) is associated with a dysregulated

76 is of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is based on clinical criteria, ye

77 Chronic fatigue syndrome (CFS) is characterized by severe fatigu

78 Das Gupta, analyzed DNA samples from chronic fatigue syndrome (CFS) patients and healthy controls.

79 ifferences in the immune function of chronic fatigue syndrome (CFS) patients are detectable in rigoro

80 Chronic fatigue syndrome (CFS) remains poorly understood.

81 te sinusitis (n = 25), subjects with chronic fatigue syndrome (CFS) with nonallergic rhinitis (n = 14

82 ction may be common in patients with chronic fatigue syndrome (CFS).

83 es of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).

84 d in the treatment and management of chronic fatigue syndrome (CFS).

85 fatigue, a small number suffer from chronic fatigue syndrome (CFS).

86 hed criteria used to define cases of chronic fatigue syndrome (CFS).

87 kine, is suspected to play a role in chronic fatigue syndrome (CFS).

88 r to those reported by patients with chronic fatigue syndrome (CFS).

89 with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).

90 in a high percentage of humans with chronic fatigue syndrome (CFS).

91 clear cells (PBMCs) of patients with chronic fatigue syndrome (CFS).

92 resent in the blood of patients with chronic fatigue syndrome (CFS).

93 have been controversially linked to chronic fatigue syndrome (CFS).

94 pears to be a potent risk factor for chronic fatigue syndrome (CFS).

95 Certain infections can trigger chronic fatigue syndromes (CFS) in a minority of people infected

96 s were recruited from six specialist chronic fatigue syndrome clinics in the UK National Health Servi

97 understanding the pathophysiology of chronic fatigue syndrome continue to demonstrate the involvement

98 o, 2.32 [95% CI, 1.02 to 5.27]); the chronic fatigue syndrome (deployed, 1.6%; nondeployed 0.1%; odds

99 measures included fibromyalgia, the chronic fatigue syndrome, dermatologic conditions, dyspepsia, ph

100 Patients with chronic fatigue syndrome experience significant functional impai

101 The prevalence of fatigue syndromes fell from 7.99 to 1.69 as somatic crit

102 Conditions examined were the chronic fatigue syndrome, fibromyalgia, the irritable bowel synd

103 We identified 2147 cases of chronic fatigue syndrome from CRIS and 17 deaths from Jan 1, 200

104 lth and Care Excellence criteria for chronic fatigue syndrome from two secondary-care clinics in the

105 Although chronic fatigue syndrome has significant symptom overlap and com

106 12 as part of the Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Int

107 tality in individuals diagnosed with chronic fatigue syndrome in secondary and tertiary care using da

108 m', 'Functional somatic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromya

109 Chronic fatigue syndrome is a controversial condition especially

110 across many domains, suggesting that chronic fatigue syndrome is a heterogeneous condition of complex

111 Chronic fatigue syndrome is an illness characterized by disablin

112 Myalgic encephalomyelitis/chronic fatigue syndrome is an unexplained debilitating disorder

113 Chronic fatigue syndrome is diagnosed on the basis of symptoms.

114 The prevalence of chronic fatigue syndrome is much less than that of fibromyalgia.

115 the pathophysiology and treatment of chronic fatigue syndrome is reviewed.

116 Treatment for chronic fatigue syndrome is symptom-based and includes pharmacol

117 Mortality associated with chronic fatigue syndrome is uncertain.

118 Chronic fatigue syndrome is unlikely to be caused or maintained

119 Reports of mild hypocortisolism in chronic fatigue syndrome led us to postulate that low-dose hydro

120 erception of health as fair or poor, chronic fatigue syndrome-like illness, and posttraumatic stress

121 In some patients with chronic fatigue syndrome, low-dose hydrocortisone reduces fatigu

122 nce also is beginning to emerge that chronic fatigue syndrome may be familial.

123 essment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we relied on expert clinician d

124 ts with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), the data are limited and cont

125 tates have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

126 chizophrenia (SZ), anxiety disorder, chronic fatigue syndrome, multiple sclerosis, amyotrophic latera

127 Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a

128 the following 5 groups of patients: chronic fatigue syndrome (n = 32), human immunodeficiency virus

129 nesis of non-GI autoimmune diseases, chronic fatigue syndrome, obesity and even some neuropsychiatric

130 ation between XMRV and patients with chronic fatigue syndrome or chronic immunomodulatory conditions.

131 hat predicted either the empirically defined fatigue syndrome or mood disorders.

132 ssociated syncope, eating disorders, chronic fatigue syndrome, or history of congenital heart disease

133 cancer patients and in the blood of chronic fatigue syndrome patients.

134 n-diagnosed multisymptom conditions: chronic fatigue syndrome, posttraumatic stress disorder, multipl

135 elop chronic fatigue, referred to as Q fever fatigue syndrome (QFS).

136 cancer and myalgic encephalomyelitis/chronic fatigue syndrome, recent data indicate that results inte

137 ificantly lower in the subjects with chronic fatigue syndrome regardless of the presence or absence o

138 way in which chronic fatigue and the chronic fatigue syndrome relate to each other: Is one the severe

139 virus (XMRV) in prostate cancer and chronic fatigue syndrome reported in previous studies remains co

140 Trans-NIH Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Research Working Group.

141 The assessment and treatment of chronic fatigue syndrome should be multidimensional and tailored

142 increased risk for fibromyalgia, the chronic fatigue syndrome, skin conditions, dyspepsia, and a clin

143 ations are a cause or consequence of chronic fatigue syndrome still remains unanswered.

144 health, or had a history of obesity, chronic fatigue syndrome, substance abuse, an eating disorder, o

145 T cells and B cells of patients with chronic fatigue syndrome, suggesting an association between XMRV

146 ed whether narrow definitions of unexplained fatigue syndromes that require additional minor somatic

147 Definitions of unexplained fatigue syndromes that require more somatic criteria sel

148 War syndrome, chronic whiplash, the chronic fatigue syndrome, the irritable bowel syndrome, and fibr

149 e, and this is probably true for the chronic fatigue syndrome, too.

150 MRV, in blood cells of patients with chronic fatigue syndrome," two of the coauthors, Silverman and D

151 d rest were associated with, or predicted, a fatigue syndrome up to 2 months after onset.

152 esearch on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome was cosponsored by the NIH Office of Di

153 herapy versus relaxation therapy for chronic fatigue syndrome were invited to complete self-rated mea

154 patients meeting Oxford criteria for chronic fatigue syndrome were recruited from six secondary-care

155 0.60-2.73; p=0.45) in patients with chronic fatigue syndrome when compared with the general populati

156 y research supports the notion of a discrete fatigue syndrome which can be distinguished from depress

157 patients meeting Oxford criteria for chronic fatigue syndrome who were recruited from six secondary c

158 ticipate that discrete causes of the chronic fatigue syndrome will be found in the future, even if th

159 patients met our strict criteria for chronic fatigue syndrome without co-morbid psychiatric disorder.